ClinicalTrials.gg
CompletedNCT07699133Updated Nov 9, 2026

Effect of Controlled Hypotension on GFAP and Cognition in Rhinoplasty

An observational study in Nasal Septum Deviation, Rhinoplasty and Induced Hypotension, sponsored by Kahramanmaras Sutcu Imam University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Kahramanmaras Sutcu Imam University · Observational

How we know

Updated Nov 9, 2026Now CompletedFirst site in Turkey (Türkiye)+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Hypotension with a site in Turkey — 34 open to participants now, 35 under way, none of them phase 3. Hypotension · Turkey.

Enrollment
53rd of 62
40 · median 100
Started
2026
with 23 others
Observational
62 of 96
24 open now
Registered
79th of 96
by date
Lead sponsor
4 of 96
Kahramanmaras Sutcu Imam University

Among the 96 studies in Hypotension with a site in Turkey, this one is the 53rd largest by enrollment of the 62 observational ones that give a count, is one of 24 that started in 2026, is one of 62 observational ones, and was the 79th registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

34 of the 96 studies in Hypotension with a site in Turkey are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Hypotension with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational study aims to evaluate the neurological safety of controlled hypotension (Mean Arterial Pressure 50-65 mmHg) during elective rhinoplasty. The investigators will assess whether this standard intraoperative hypotensive strategy causes cellular stress by measuring serum Glial Fibrillary Acidic Protein (GFAP) levels and early postoperative cognitive changes using the Montreal Cognitive Assessment (MoCA) test.

Read the detailed description

Controlled hypotension is frequently utilized in rhinoplasty to minimize bleeding and improve the surgical field. However, the potential cellular stress on the brain due to reduced cerebral perfusion is not fully understood. This study will enroll 40 ASA I-II patients undergoing elective rhinoplasty under general anesthesia with sevoflurane. Blood samples will be drawn at baseline (after anesthesia induction) and 24 hours postoperatively to measure serum GFAP levels via ELISA. Cognitive functions will be evaluated simultaneously using the MoCA test. The primary objective is to determine the change in GFAP concentrations, and the secondary objective is to evaluate its correlation with early postoperative cognitive scores.

03

Conditions studied

  • Nasal Septum Deviation
  • Rhinoplasty
  • Induced Hypotension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients, aged 18 to 50 years, who are scheduled to undergo elective primary rhinoplasty or septorhinoplasty under general anesthesia at the Department of Otorhinolaryngology and Plastic Surgery, Kahramanmaras Sutcu Imam University Hospital. Patients will be selected from those with an American Society of Anesthesiologists (ASA) physical status of I or II, ensuring a healthy cohort without severe systemic diseases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for elective rhinoplasty or septorhinoplasty under general anesthesia.
  • I or II.
  • Literate and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • History of neurological (e.g., cerebrovascular event, epilepsy) or psychiatric diseases.
  • Total septal reconstruction requiring costal (rib) cartilage grafts.
  • Expected surgical duration exceeding 3 hours.
  • Preoperative severe cognitive impairment.
  • Pregnancy or lactation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Controlled Hypotension Cohort

    Patients undergoing elective rhinoplasty receiving standard intraoperative controlled hypotension (Target MAP: 50-65 mmHg) maintained with sevoflurane and remifentanil.

    Procedure: Controlled Hypotension (Standard of Care)

Interventions

  • ProcedureControlled Hypotension (Standard of Care)

    Maintenance of Mean Arterial Pressure (MAP) between 50 and 65 mmHg during the surgical procedure to optimize the surgical field.

06

What researchers measure

Primary outcomes

  1. Change in Serum Glial Fibrillary Acidic Protein (GFAP) Level

    GFAP is a biomarker of astrocyte stress and blood-brain barrier permeability. Measured via ELISA (pg/mL).

    Time frame: Baseline (T0: Post-induction) and 24 hours postoperatively (T1).

Secondary outcomes

  1. Change in Montreal Cognitive Assessment (MoCA) Score

    The MoCA is a 30-point screening tool for detecting cognitive dysfunction. Higher scores indicate better cognitive function (Range: 0-30).

    Time frame: Baseline (Preoperative ward visit) and 24 hours postoperatively.

  2. Duration of Target Hypotension

    Total time (in minutes) the patient's Mean Arterial Pressure (MAP) is maintained within the target range of 50-65 mmHg.

    Time frame: Intraoperative period (from surgical incision to end of surgery, approximately 1-3 hours).

07

Study locations

1 site
  • Kahramanmaras Sutcu Imam University Hospital
    Kahramanmaraş, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in the final publication will be shared upon reasonable request. Data will only be shared for academic, non-commercial purposes to ensure compliance with personal data protection regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will become available beginning 6 months and ending 36 months following the publication of the primary research article.

Access criteria: Data will be shared with researchers who provide a methodologically sound research proposal. Requests should be directed to the corresponding author via email. Requestors will be required to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Sep 2026, 2 months.

Of 149 non-industry observational studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 2 months is below that.

Counting every sponsor, half of 154 studies reached it within 11 months; a quarter within 5 and three quarters within 25.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Feb 2027 → Sep 2026 and completion Mar 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartActual
Jul 10, 2026
Primary completionActual
Sep 30, 2026was Feb 2027
CompletionActual
Sep 30, 2026was Mar 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 9, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Kahramanmaras Sutcu Imam University Hospital · Kahramanmaraş, Turkey (Türkiye)
Nov 9, 2026
Primary completion
Feb 28, 2027→Sep 30, 2026 (actual)
Nov 9, 2026
Study completion
Mar 30, 2027→Sep 30, 2026 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Completed
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Kahramanmaras Sutcu Imam University Hospital · Kahramanmaraş, Turkey (Türkiye)
    Primary completion Feb 28, 2027→Sep 30, 2026 (now actual)
    Study completion Mar 30, 2027→Sep 30, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07699133
Responsible party
Cengizhan Yavuz (Cengizhan Yavuz, MD, Assistant Professor, Department of Anesthesiology and Reanimation, Kahramanmaras Sutcu Imam University) — Principal investigator
First posted
Jul 13, 2026
Start date
Jul 10, 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion